Monitoring people with MEN1 and related hormone gland tumors
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This study follows people who have Multiple Endocrine Neoplasia type 1 (MEN1), a genetic condition that can cause tumors in hormone glands. It aims to monitor symptoms and lesions over time to better understand how the condition progresses and how to manage it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to take part (and if you’re under 18, your parent/guardian agrees too)
- You have symptoms from MEN1, meaning at least two affected areas: parathyroid, pancreas, or pituitary
- Or you have a known MEN1-related tumor plus a confirmed MEN1 gene mutation
- Or you have a tumor and a confirmed family history of MEN1
- If you have no symptoms, you still may qualify if you have a confirmed MEN1 gene mutation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with Multiple Endocrine Neoplasia type 1 (MEN1) over time, including those with symptoms, certain isolated hormone gland problems, and people without symptoms who have the MEN1 gene change. It may help doctors learn how MEN1 starts and progresses so care can be better timed and personalized.
This study is testing a new blood test to see if it can help diagnose neuroendocrine tumors in people with MEN1, a genetic condition that increases the risk of these tumors. The test looks for a protein called hPG80 (progastrin) and may help doctors find tumors earlier.
This study is building a database of patients with MEN1 syndrome, a genetic condition that increases the risk of tumors in glands like the pancreas, pituitary, and parathyroid. By collecting information, researchers hope to better understand the disease and improve future care for patients.
This study looks at blood chemistry (metabolomics) and genetic information in people who have MEN1, especially if they are being evaluated for pancreatic neuroendocrine tumors. It may help doctors better diagnose these tumors by finding patterns in test results.
This study is tracking patients with advanced neuroendocrine tumors to see which treatments help them live longer without severe side effects, and how these side effects affect daily life. It aims to find the best treatment approaches for people like you.
This study looks at neuroendocrine tumors by collecting tissue (when available) and tracking how the disease behaves over time. It may help researchers better understand these cancers, including rare cases of adrenocortical cancer.
Hear when a new MEN1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.